LivaNova PLC - Asset Resilience Ratio
LivaNova PLC (LIVN) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Explore LIVN long-term investment intensity to see how much of total assets are deployed in long-term investments.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2022)
This chart shows how LivaNova PLC's Asset Resilience Ratio has changed over time. See LIVN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down LivaNova PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LIVN total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $42.00K | 0.0% |
| Total Liquid Assets | $42.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: LivaNova PLC maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
LivaNova PLC Industry Peers by Asset Resilience Ratio
Compare LivaNova PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
GN Store Nord
CO:GN |
Medical Devices | -4.56% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Nanjing Medlander Medical Technology Co. Ltd. A
SHG:688273 |
Medical Devices | 34.29% |
|
Ningbo David Medical Device Co Ltd
SHE:300314 |
Medical Devices | 6.89% |
|
Pulsenmore Ltd. Ordinary Shares
NASDAQ:PLSM |
Medical Devices | 46.67% |
Annual Asset Resilience Ratio for LivaNova PLC (1998–2022)
The table below shows the annual Asset Resilience Ratio data for LivaNova PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | $-34.00K | $2.29 Billion | 0.00pp |
| 2021-12-31 | 0.00% | $-2.00K | $2.20 Billion | -1.30pp |
| 2020-12-31 | 1.30% | $31.09 Million | $2.40 Billion | +1.19pp |
| 2018-12-31 | 0.10% | $2.65 Million | $2.55 Billion | -0.01pp |
| 2017-12-31 | 0.12% | $2.94 Million | $2.50 Billion | +0.12pp |
| 2016-12-31 | 0.00% | $-8.00K | $2.34 Billion | -0.27pp |
| 2015-12-31 | 0.27% | $7.00 Million | $2.56 Billion | -8.23pp |
| 2014-12-31 | 8.51% | $25.03 Million | $294.19 Million | 0.00pp |
| 2013-12-31 | 8.51% | $25.03 Million | $294.19 Million | +2.79pp |
| 2012-12-31 | 5.72% | $15.10 Million | $264.04 Million | -1.36pp |
| 2011-12-31 | 7.08% | $15.00 Million | $211.91 Million | +6.60pp |
| 2009-12-31 | 0.48% | $1.00 Million | $207.47 Million | -0.20pp |
| 2008-12-31 | 0.68% | $1.00 Million | $146.21 Million | -0.27pp |
| 2007-12-31 | 0.95% | $1.00 Million | $105.19 Million | +0.22pp |
| 2006-12-31 | 0.73% | $1.00 Million | $136.23 Million | +0.08pp |
| 2005-12-31 | 0.66% | $1.00 Million | $152.30 Million | -22.41pp |
| 2004-12-31 | 23.06% | $22.80 Million | $98.86 Million | +22.98pp |
| 2000-12-31 | 0.08% | $57.54K | $67.99 Million | -3.80pp |
| 1999-12-31 | 3.89% | $1.56 Million | $40.00 Million | -44.35pp |
| 1998-12-31 | 48.24% | $19.20 Million | $39.80 Million | -- |
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. … Read more